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A B S T R A C T
Background: While chronic subclinical inﬂammation is now considered to be a predisposing risk factor
of cardiovascular diseases, the extent by which adipokines induce metabolic abnormalities in humans
is not fully resolved. The purpose of this study was to examine the relationship between insulin resis-
tance and serum inﬂammatory markers in obese subjects.
Methods: One hundred and ﬁve subjects without any clinically evident CVD were classiﬁed into 3 cor-
onary risk levels according to Framingham risk score. Demographic and anthropometric variables were
estimated. Serum levels of lipid proﬁle, blood glucose, insulin, omentin-1 and high sensitivity-C reac-
tive protein (hs-CRP) weremeasured in fasting blood samples. Insulin resistance indices were also calculated.
Results: 29% and 62% of the study population were overweight and obese respectively by body mass index
(BMI) measures. Almost half of the study population was considered diabetic. There was a tendency for
a fall in serum omentin-1 concentrations with increasing coronary risk with a signiﬁcant increase in hs-
CRP levels in the same direction (p < 0.05). Age and fasting blood glucose were found to be independently
associated with serum omentin-1 levels. BMI and fasting blood glucose were independent determi-
nants of serum hs-CRP levels.
Conclusions: Omentin-1 might be associated with the development of diabetes mellitus indirectly via
insulin activity and obesity. These ﬁndings may have important implications for the pathophysiology and
therapy of diabetes mellitus by further longitudinal studies.
© 2015 Published by Elsevier Inc.
Introduction
Adipose tissue is a dispersed endocrine organ, and a source of
several hormones, for example leptin, and a number of cytokines
known to be involved in systemic inﬂammation; these include plas-
minogen activator inhibitor type 1 (PAI-1), interleukin 6 (IL-6), and
tumor necrosis factor α (TNF-α) [1].
Cardiovascular disease (CVD) is now recognized to be a process in-
volving inﬂammatory processes, and serum inﬂammatorymarkers are
considered to be important for the evaluation of cardiovascular risk [2].
It is possible that the relationship between CVD risk and obesity
is linked by the increased inﬂammatory milieu [3]. Obesity related
inﬂammation has also been proposed as a possible mechanism by
which obesity increases insulin resistance and leads to diabetes [4].
While chronic subclinical inﬂammation is now considered to be
a predisposing risk factor of CVD [5], the extent by which adipokines
induce metabolic abnormalities in humans is not fully resolved [6].
Omentin-1 is a circulating adipokine that is down-regulated in
patients with CVD. Decreased omentin expression was shown to be
implicated in a variety of chronic inﬂammatory diseases [7,8], and
has been identiﬁed as an adipokine that may improve insulin sen-
sitivity [9], although its circulating levels in obesity have not been
adequately studied and its correlation with insulin resistance or
obesity is still controversial.
We hypothesized that insulin resistance in obese subjects is as-
sociatedwith higher serum concentrations of inﬂammatory cytokines
and that the association of cytokines with insulin sensitivity may
be independent of body fat mass.
The purpose of this study was to examine the relationship




One hundred and ﬁve subjects, attending the outpatient clinic
in King Abdulaziz University Hospital, who were without any
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clinically evident CVD were considered for inclusion in this study.
All patients gave their written informed consent for participation
in the study, and the ethics committee at KAUH approved the study
protocol.
Exclusion criteria included subjects with liver, kidney, thyroid,
malignancy, acute, or chronic infectious or inﬂammatory diseases.
Subjects taking medications, such as statins and aspirin that could
affect inﬂammatory markers levels, were also excluded from the
study.
The Framingham risk score used in this study is a version deﬁned
in the ATP III report and is a composite score of traditional cardio-
vascular risk factors that includes age and sex, systolic blood pressure,
total cholesterol, HDL-C, presence of diabetes, and smoking status
[10].
Anthropometric measurements
Clinical assessment included anthropometric measurements and
blood pressure readings. Data on health status were obtained from
medical ﬁles and supplemented by the participants’ self-reported
health-related data. Body weight, height, body mass index (BMI),
waist circumference, hip circumference, and waist to hip circum-
ference ratio (WHR) were estimated for all study subjects. Body
height and weight were measured using a stadiometer and a stan-
dardized balance-beam scale, respectively. Waist circumference was
measured at the level of the umbilicus with silent breathing, and
hip circumference was measured at the inter-trochanteric girth ac-
cording to the WHO guideline [11] in standing position. BMI was
calculated as weight (kg) divided by height (m2), andWHR was ob-
tained from waist circumference divided by hip circumference.
Gender-based waist circumference and WHR cutoffs were em-
ployed as a measure of cardiovascular risk [12].
Blood pressure measurements were obtained on each subject fol-
lowing a 10-minute rest period in a seated position using
auscultation and a mercury sphygmomanometer. The average of
three successive readings of systolic and diastolic pressure was used
as the documented blood pressure values.
Biochemical tests
Blood samples were collected from all participants after a 12-
hour overnight fasting into plain and EDTA tubes. Fasting blood
glucose levels were measured using an automated analyzer (Di-
mension Vista System, Siemens, Germany) standard enzymatic
methods. Fasting insulin was measured using an enzyme ampli-
ﬁed chemiluminescence assay (Modular E170 immunoassay analyzer,
Roche, USA).
The homeostasis model assessment of insulin resistance
(HOMA-IR) and the homeostasis model assessment of β-cell insulin
secretion (HOMA-IS) were calculated from fasting insulin and glucose
levels using the following equations: HOMA-IR = fasting insulin
(mU/L) × fasting blood glucose (mmol/L) / 22.5; HOMA-
IS = [20 × fasting Insulin (mU/L)] / [fasting blood glucose (mmol/L)
− 3.5] [13]. Quantitative insulin sensitivity check index (QUICKI)
was calculated by (QUICKI = 1/ [log (fasting insulin) + log (fasting
glucose)] [14].
A residual aliquot of serum from the fasting blood sample on each
participant was stored at −80 °C. Serum high sensitive C-reactive
protein (hs-CRP) was measured by means of immunoturbidimetric
assay (Behring Nephelometer-BNA2, Siemens, USA).
Serum omentin-1wasmeasured by ELISA in duplicate using com-
mercially available kits (Biovendor, Germany). The intra-assay CV
was 3.2%, and inter-assay CV was 4.4%.
Statistical analysis
Continuous variables are expressed as mean ± standard devia-
tion. Categorical variables were expressed as percentage.
Kolmogorov–Smirnov test was performed to verify the normal dis-
tribution of the data. Logarithmically transformed values were used
for the statistical analysis.
ANOVA test for normally distributed parameters or Kruskal–
Wallis test for non-normally distributed parameters was used to
compare mean values of continuous variables in between the sub-
groups followed by Bonferroni’s test. Categorical variables were
compared by χ2 or Fisher exact tests as appropriate. Correlations
between continuous variables were assessed with the use of Pearson
correlation test or Spearman correlation rank test as appropriate.
Multiple stepwise regression analysis was performed to deter-
mine signiﬁcant confounding factors for serum hs-CRP and
omentin-1 levels. P values <0.05 were considered to be statistical-
ly signiﬁcant. All the statistical analyses were performed using SPSS
version 16 software (SPSS Inc., Chicago, IL, USA).
Results
The study cohort consisted of 105 participants, aged 40–78 years,
73% of whom were females and 27% were males. Ten percent were
lean, 29% were overweight, and 62% were obese according to their
respective BMI classes namely; 18.5–24.9 kg/m2; 25–29.9 kg/m2; and
≥30 kg/m2. Approximately 66% of the male subjects had a waist cir-
cumference >102 cm in comparison with 95% of the female subjects
with waist circumference >88 cm. Alternatively, 43% of males had
WHR ≥ 0.95, whereas 97% of females had WHR ≥ 0.80.
In further analysis, the patients were divided into those with low
coronary risk (n = 62), those with intermediate coronary risk (n = 25),
and those with high coronary risk (n = 18) based on their Framing-
ham score of 10-year CVD risk.
Table 1 provides clinical characteristics of the study partici-
pants. Those with low coronary risk had signiﬁcantly lower body
height andWHR values than those with high coronary risk (p < 0.05).
Additionally, signiﬁcant differences in age and blood pressure read-
ings existed between the low coronary risk group versus the
remaining groups (p < 0.05).
Although no signiﬁcant differences inmean levels of fasting blood
glucose, fasting insulin, and/or insulin resistance indices were found
across the subgroups, 44% of the study participants were consid-
ered diabetic with fasting blood glucose ≥7 mmol/L (Table 2).
Notably, there was a trend for a lower mean serum omenin-1
concentration with the increasing coronary risk as shown in Fig. 1a,
though this did not reach statistical signiﬁcance. Furthermore, this
was accompanied by a signiﬁcant increase in serum hs-CRP levels
(p < 0.05) between subjects with low, intermediate, and high cor-
onary risk (Fig. 1b).
Table 2 shows correlation analysis of the measures of body fat
and insulin resistance with serum hs-CRP and omentin-1 levels.
There were signiﬁcant associations between circulating omentin-1
levels and age, fasting blood glucose, HOMA-IR, and QUICK-I.
However, there were no association between serum hs-CRP and
omentin-1 levels. Serum hs-CRP levels were signiﬁcantly associ-
ated with anthropometric measurements including body
weight, BMI, waist and hip circumferences, and fasting blood
glucose.
When multiple regression analysis was performed to deter-
mine which variables were independently associated with serum
omentin-1 levels, age and fasting blood glucose remained signiﬁ-
cant (Table 3). Table 4 shows that BMI and fasting blood glucose
were independent determinants of serum hs-CRP levels.
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Discussion
Several adipokines have been proposed to be linked directly to
insulin resistance and obesity [1]. Measurement of their serum levels
may be an early marker for atherosclerosis risk. Serum hs-CRP levels
have been used as a marker of subclinical inﬂammation which is
expected to identify subjects at early stages of CVD [15]. Indepen-
dent roles of these risk factors in the development of atherosclerosis
are not, however, fully understood.
Dysregulated production of adipocytokines is linked to the patho-
genesis of cardiovascular risk factors such as diabetes mellitus [16].
Themain ﬁndings of this present study are that fasting blood glucose
was independently associated with hs-CRP (β = 0.227, p < 0.05) as
well as omentin-1 (β = 0.254, p < 0.01) in the study subjects. Our
data indicate that obesity and inﬂammation are closely associated
with glucose metabolism impairment [17]. It has previously been
proposed that obesity is causally linked to a chronic low-grade in-
ﬂammatory state, which contributes to the development of metabolic
dysfunction [6,18].
It is unclear why omentin-1 and hs-CRP levels were not corre-
lated with each other, but adipose tissue is known to secrete several
adipokines that have important roles in the initiation of insulin re-
sistance or endothelial dysfunction [19,20]. Therefore, measurement
of visceral adipose mass and/or levels of other adipokines in future
studies could help elucidate why these two markers did not cor-
relate together in our study.
Levels of inﬂammatory cytokines (like TNF-α and IL-6) were found
to be increased in obese and diabetic subjects [21]. Serum omentin-1
levels have been shown to be associated with obesity-related met-
abolic and vascular complications [22]. Overall, overweight and
obesity were highly prevalent among the study population. In the
current study, BMI was only an independent correlate of hs-CRP level
(β = 0.369, p < 0.0001).
Serum omentin-1 levels were previously reported to be signiﬁ-
cantly reduced in obese compared with lean individuals in one study
[23] but were similar between these groups in another study [24].
No association was observed between omentin-1 levels and mea-
sures of body fat (Table 2). It was suggested that obesity negatively
regulates omentin expression [25]. Insulin resistance has been shown
to be associated with pro-inﬂammatory states [26]. Inﬂammatory
cytokines may contribute to the regulation of omentin-1 levels [27].
Table 1








Gender (F:M) 62 (56:6) 25 (18:7) 18 (3:15) <0.0001
Age (years) 54.1 ± 0.8 60.2 ± 1.7 60.4 ± 2.1 <0.0001
SBP (mmHg) 126.8 ± 2.1 144.3 ± 3.7 154.4 ± 4.9 <0.0001
DBP (mmHg) 76.4 ± 1.4 85.3 ± 2.7 85.6 ± 3.9 <0.01
Body weight (Kg) 83.8 ± 2.2 82.8 ± 3.9 86.2 ± 5.6 NS
Body height (cm) 159.2 ± 0.9 158.5 ± 1.6 164.6 ± 1.9 <0.05
BMI (Kg/m2) 33.1 ± 0.8 32.9 ± 1.4 31.6 ± 1.6 NS
BMI cut-off levels
Normal (18.5–24.9 kg/m2) 4 (7) 3 (12) 3 (17) NS
Overweight (25–29.9 kg/m2) 18 (29) 7 (28) 5 (28)
Obese (≥30 kg/m2) 40 (65) 15 (60) 10 (56)
Waist circumference (cm) 106.6 ± 1.4 107.7 ± 3.3 108.6 ± 3.1 NS
Hip circumference (cm) 116.4 ± 1.6 116.2 ± 4.2 112.4 ± 2.6 NS
WHR 0.92 ± 0.0 0.94 ± 0.0 0.96 ± 0.0 <0.05
TC (mmol/L) 4.66 ± 0.13 5.04 ± 0.25 4.70 ± 0.34 NS
HDL-C (mmol/L) 1.21 ± 0.04 1.15 ± 0.05 1.06 ± 0.04 NS
LDL-C (mmol/L) 2.69 ± 0.11 3.01 ± 0.23 2.93 ± 0.29 NS
TG (mmol/L) 1.67 ± 0.11 1.94 ± 0.14 1.58 ± 0.16 NS
FBG (mmol/L) 7.2 ± 0.3 7.9 ± 0.5 7.3 ± 0.6 NS
FBG cut-off levels
Normal (<6.1 mmol/L) 30 (48) 9 (36) 3 (17) NS
IGT (6.1–< 7 mmol/L) 7 (11) 3 (12) 6 (33)
DM (≥7 mmol/L) 25 (40) 13 (52) 9 (43)
Fasting insulin (μU/ml) 16.4 ± 1.2 17.9 ± 4.0 18.8 ± 3.2 NS
HOMA-IR 5.64 ± 0.7 7.05 ± 2.1 6.02 ± 1.1 NS
HOMA-IS 133.8 ± 15.6 93.1 ± 13.6 121.4 ± 19.0 NS
QUICK-I 0.31 ± 0.0 0.31 ± 0.0 0.31 ± 0.0 NS
Data are given as the mean ± SD or as the number of subjects with percentages given in parentheses, as appropri-
ate. Categorical data are compared by χ2 test; continuous variables are compared by Kruskal–Wallis test. BMI, body
mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment
insulin resistance index; HOMA-IS, homeostasis model assessment of β-cell insulin secretion; NS, non-signiﬁcant;
SBP, systolic blood pressure; WHR, waist–hip ratio.
Table 2
Correlation analysis of measures of body fat and insulin resistance with serum hs-
CRP and omentin-1 levels in the study participants (N = 105)
hs-CRP (mg/L) Omentin-1 (ng/ml)
r p r p
Age (years) −0.058 0.556 0.261 0.007
SBP (mmHg) 0.136 0.169 −0.106 0.281
DBP (mmHg) −0.012 0.906 −0.049 0.620
Body weight (Kg) 0.340 <0.0001 −0.112 0.257
Body height (cm) −0.120 0.224 −0.049 0.621
BMI(Kg/m2) 0.394 <0.0001 −0.055 0.580
Waist circumference (cm) 0.236 0.015 0.061 0.541
Hip circumference (cm) 0.282 0.004 0.00- 0.981
WHR 0.110 0.266 −0.037 0.706
FBG (mmol/L) 0.269 0.006 0.260 0.008
Fasting insulin (μU/ml) 0.101 0.311 −0.024 0.812
HOMA-IR 0.069 0.484 0.233 0.018
QUICK-I −0.183 0.064 −0.233 0.018
Signiﬁcant correlations are shown in bold font. BMI, body mass index; DBP, dia-
stolic blood pressure; FBG, fasting blood glucose; HOMA-IR, homeostasis model
assessment insulin resistance index; HOMA-IS, homeostasis model assessment of
β-cell insulin secretion; NS, non-signiﬁcant; SBP, systolic blood pressure;WHR, waist–
hip ratio.
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Many studies have shown that omentin-1 levels are negatively cor-
related with BMI, waist circumference, fasting insulin, and HOMA-
IR index [23,28]. However, in the current study, estimates of insulin
resistance were derived using the HOMA-IR and QUICK-I, and were
signiﬁcantly related to serum omentin-1 values (r = 0.233, p < 0.05;
r=-0.233, p < 0.05 respectively).
The Framingham risk score is a conventional means of predict-
ing coronary risk in the general population [29]. Therefore,
adipocytokines levels association with the presence and extent of
coronary risk could independently predict the future risk of ath-
erosclerotic diseases. Despite the lack of statistical difference in serum
omentin-1 levels among the study population as stratiﬁed by the
Framingham coronary risk score, there seems to be a tendency for
a fall in serum omentin-1 concentrations with increasing coro-
nary risk (Fig. 1a). Several biomarkers, such as hs-CRP, have been
shown to enhance Framingham risk score algorithms and were as-
sociated with increased cardiovascular risk [30]. Consequently,
determination of circulating levels of novel markers like omentin-1
could has additional value in the prediction of future risk of CVD.
Conclusion
Our ﬁndings suggest that omentin-1 might be associated with
the development of diabetes mellitus indirectly via insulin activi-
ty and obesity. These ﬁndings may have important implications for
the pathophysiology and therapy of diabetes mellitus. However, due
to the nature of the current study design, which does not allow us
to infer causality between obesity and inﬂammation, omention-1,
longitudinal studies are warranted.
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